- Home
- HUMA vs PLX Comparison
HUMA vs PLX Comparison
Compare HUMA & PLX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | HUMA | PLX |
|---|---|---|
| Founded | 2004 | 1993 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 165.7M | 207.1M |
| IPO Year | 2020 | 1996 |
Fundamental Metrics
Financial Performance| Metric | HUMA | PLX |
|---|---|---|
| Price | $0.43 | $2.56 |
| Analyst Decision | Buy | |
| Analyst Count | 5 | 0 |
| Target Price | ★ $1.63 | N/A |
| AVG Volume (30 Days) | ★ 5.7M | 836.2K |
| Earning Date | 11-11-2026 | 08-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 79.37 | N/A |
| EPS | N/A | ★ 0.27 |
| Revenue | $2,038,000.00 | ★ $52,744,000.00 |
| Revenue This Year | $72.32 | $55.77 |
| Revenue Next Year | $518.79 | N/A |
| P/E Ratio | ★ N/A | $9.46 |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $0.34 | $1.65 |
| 52 Week High | $1.78 | $3.19 |
Technical Indicators
Market Signals| Indicator | HUMA | PLX |
|---|---|---|
| Relative Strength Index (RSI) | 41.96 | 42.44 |
| Support Level | $0.34 | $2.21 |
| Resistance Level | $0.46 | $2.75 |
| Average True Range (ATR) | 0.04 | 0.10 |
| MACD | 0.01 | -0.02 |
| Stochastic Oscillator | 55.07 | 19.67 |
Price Performance
Historical ComparisonAbout HUMA Humacyte Inc.
Humacyte Inc is developing a commercial-stage biotechnology platform to deliver universally implantable bioengineered human tissues and organs designed to improve the lives of patients and transform the practice of medicine. It develops and manufactures acellular tissues to treat a wide range of diseases, injuries, and chronic conditions. Company's pipeline includes Vascular Trauma, PAD, Dailysis, Acellular Tissue Engineered Vessels, Organ Systems, Advanced Tissue Constructs.
About PLX Protalix BioTherapeutics Inc. (DE)
Protalix BioTherapeutics Inc is a commercial-stage biopharmaceutical company focused on the discovery, development, production, and commercialization of therapeutics for rare diseases with important unmet needs. ProCellEx, a proprietary plant cell-based protein expression system, represents a new method for developing recombinant proteins in an industrial-scale manner. corporate includes the development of treatments for rare and orphan diseases. The Company operates as a single operating segment in Israel.